Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia Novartis Accessed on 4 Jan 2012 from http://www.novartis.is/newsroom/media-releases/en/2011/1481634.shtml. CommentRecommendBookmarkWatch